Parenti Nicola, Bartolacci Silvia, Carle Flavia, Angelo Fanciulli
Department of Emergency Medicine, Community Hospital Maurizio Bufalini, Cesena, Italy.
Intern Emerg Med. 2008 Mar;3(1):43-7. doi: 10.1007/s11739-008-0092-8. Epub 2008 Feb 14.
Despite evidence that cardiac troponin I (cTnI) identifies patients with advanced heart failure (HF) at risk of death, data on heterogeneous HF populations are scarce. Our purpose was to verify and analyze the prognostic role of cTnI in acute HF patients admitted to the emergency department. This was an observational longitudinal prospective study carried out in an urban hospital. We studied 99 patients discharged from the department between March and December 2002 with a HF diagnosis and samples of cTnI. Patients with acute coronary syndromes, myocarditis or renal failure were excluded. The main outcome was death from any cause. The detection level of the cTnI assay was 0.05 ng/ml. cTnI was detected in 45.5% of HF patients. These patients had a higher NYHA class (P<0.001) at initial presentation and longer hospitalization (P=0.004) than cTnI-negative patients. Nineteen deaths occurred during the study: 17 for HF and 2 for acute coronary syndrome. Finally, detectable cTnI was associated with increased mortality risk (RR 4.7; 95% CI 1.3-17.1; P=0.021) also after adjustment for other adverse prognosis factors (age, NYHA class and presence of relapses). Our HF cTnI-positive patients had a worse clinical presentation and longer hospitalization. cTnI is a significant independent predictor of death and of longer hospitalization. It could be used for the early identification of HF patients at an increased risk of death in the long term, and of longer hospitalization. Thus, cTnI can aid decision-making and clinical management in the emergency department.
尽管有证据表明心肌肌钙蛋白I(cTnI)可识别有死亡风险的晚期心力衰竭(HF)患者,但关于异质性HF人群的数据却很稀少。我们的目的是验证和分析cTnI在急诊科收治的急性HF患者中的预后作用。这是一项在城市医院进行的观察性纵向前瞻性研究。我们研究了2002年3月至12月间从该科室出院的99例诊断为HF且有cTnI样本的患者。排除急性冠状动脉综合征、心肌炎或肾衰竭患者。主要结局是任何原因导致的死亡。cTnI检测的检测水平为0.05 ng/ml。45.5%的HF患者检测到cTnI。这些患者在初次就诊时纽约心脏协会(NYHA)分级更高(P<0.001),住院时间更长(P=0.004),高于cTnI阴性患者。研究期间发生了19例死亡:17例死于HF,2例死于急性冠状动脉综合征。最后,在调整其他不良预后因素(年龄、NYHA分级和复发情况)后,可检测到的cTnI也与死亡风险增加相关(相对危险度4.7;95%可信区间1.3 - 17.1;P=0.021)。我们cTnI阳性的HF患者临床表现更差,住院时间更长。cTnI是死亡和住院时间延长的重要独立预测因素。它可用于早期识别长期死亡风险增加和住院时间延长的HF患者。因此,cTnI有助于急诊科的决策制定和临床管理。